Opioid Use Disorder Treatment Linkage at Sexual Health Clinics Using Buprenorphine

• Status: Not yet recruiting
• Trial end date: 2025-03-15
• Target enrollment: 0
• Participant gender: All

Summary

This study will examine the effectiveness of opioid use disorder (OUD) treatment linkage strategies for patients seen at sexual health clinics. This 3-arm RCT will compare Usual Care vs. Patient Navigation vs. Patient Navigation + Buprenorphine Initiation (UC vs. PN vs. PN+BUP).

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Friends Research Institute, Inc.
• Collaborators: Baltimore City Health Department; National Institute on Drug Abuse (NIDA)
• Treatments: Buprenorphine; Buprenorphine, Naloxone Drug Combination; Naloxone

Criteria

Inclusion Criteria:

1. Age 18 or older

2. Opioid use in the past 30 days

3. DSM-5 diagnostic criteria for OUD with physiological dependence

4. Willing to try buprenorphine treatment.

Exclusion Criteria:

1. current enrollment in OUD treatment with buprenorphine, methadone, or extended-release naltrexone

2. clinical contraindication with buprenorphine (e.g., allergy to buprenorphine or naloxone, chronic pain management with opioid agonists)

3. regular use of illicit long-acting opioid agonists (e.g., methadone; due to potential challenges with dose induction)

4. heavy alcohol use that, in the judgement of the prescribing provider, raises a safety concern that precludes eligibility for buprenorphine induction

5. high dose or intravenous benzodiazepine misuse

6. pregnancy (due to special needs; will be treated outside of the study)

7. unstable medical or psychiatric illness (e.g., psychosis or active suicidal ideation)

8. inability to provide informed consent (e.g., failure to pass consent quiz)